Fayer JL - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.

Fayer JL, Zannikos PN, Stevens JC, Luo Y, Sidhu R, Kirkesseli S. Fayer JL, et al. J Clin Pharmacol. 2001 Mar;41(3):305-16. doi: 10.1177/00912700122010122. J Clin Pharmacol. 2001. PMID: 11269571 Clinical Trial.

Characterization of 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]methyl]quinoline N-glucuronidation by in vitro and in vivo approaches.

Stevens JC, Fayer JL, Cassidy KC. Stevens JC, et al. Among authors: fayer jl. Drug Metab Dispos. 2001 Mar;29(3):289-95. Drug Metab Dispos. 2001. PMID: 11181497

A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro.

Fayer JL, Petullo DM, Ring BJ, Wrighton SA, Ruterbories KJ. Fayer JL, et al. J Pharmacol Toxicol Methods. 2001 Sep-Oct;46(2):117-23. doi: 10.1016/s1056-8719(02)00168-5. J Pharmacol Toxicol Methods. 2001. PMID: 12481849

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Search Page

Filters